eMedicine Specialties > Pediatrics: Genetics and Metabolic Disease > Genetics

Crouzon Syndrome: Follow-up

Author: Harold Chen, MD, MS, FAAP, FACMG, Professor, Departments of Pediatrics, Obstetrics and Gynecology, and Pathology, Director of Genetic Laboratory Services, Louisiana State University Medical Center
Contributor Information and Disclosures

Updated: Sep 10, 2009

Follow-up

Further Inpatient Care

  • Admit the patient with Crouzon syndrome for surgical intervention.
  • Tracheostomy may be needed for airway management.

Further Outpatient Care

  • Carefully monitor postoperative complications.

Transfer

  • Transfer may be indicated for further diagnostic evaluation and surgical intervention.

Complications

  • Wound infections, frontal bone osteomyelitis, extradural abscess, and periorbital abscess
  • Increased intracranial pressure and postoperative hydrocephalus
  • Cerebrospinal fluid (CSF) leak
  • Respiratory distress and obstructive sleep apnea
  • Facial nerve palsy, blindness, diplopia, and velopharyngeal incompetence
  • Optic atrophy remains an important cause of visual impairment before decompressive craniectomy.

Prognosis

  • Prognosis depends on malformation severity.
    • Craniosynostosis can result in brain compression and mental retardation in severely affected individuals unless relieved by early craniectomy.
    • Innovations in craniofacial surgery have enabled patients to achieve their full potential by maximizing their opportunities for intellectual growth, physical competence, and social acceptance.
  • Patients usually have a normal lifespan.

Patient Education

Miscellaneous

Medicolegal Pitfalls

  • Failure to perform an early craniectomy
  • Failure to provide adequate genetic counseling
  • Failure to recognize premature closure of sutures early in life

Special Concerns

  • Genetic counseling should include discussion of the following:14,15
    • The risk that an affected individual will have affected offspring is 50%.
    • The recurrence risk for unaffected parents is negligible except in the case of germinal mosaicism. The risk for future siblings depends on the proportion of germ cells bearing the mutant allele.
    • An advanced paternal age effect in new mutations has been reported.
  • Prenatal diagnosis16
    • Identification of the disease-causing FGFR2 mutation allows prenatal diagnosis using chorionic villus sampling (CVS) in the first trimester or amniocentesis in the second trimester.17
    • Exophthalmos and ocular hypertelorism can be detected by ultrasonography. Prenatal diagnosis of craniosynostosis is difficult and could benefit from 3-dimensional ultrasonography and 3-demensional CT scanning.
    • Prenatal MRI has diagnostic value when synostosis is suspected based on ultrasonography findings. MRI is accurate in detection of associated brain abnormalities, which is an important prognostic issue in this disease.
    • Preimplantation genetic diagnosis for Crouzon syndrome by blastomere biopsy samples from cleavage-stage embryos may be detected by mutation analysis.
 


More on Crouzon Syndrome

Overview: Crouzon Syndrome
Differential Diagnoses & Workup: Crouzon Syndrome
Treatment & Medication: Crouzon Syndrome
Follow-up: Crouzon Syndrome
Multimedia: Crouzon Syndrome
References

References

  1. Ahmed I, Afzal A. Diagnosis and evaluation of Crouzon syndrome. J Coll Physicians Surg Pak. May 2009;19(5):318-20. [Medline].

  2. Cohen MM Jr, Kreiborg S. Birth prevalence studies of the Crouzon syndrome: comparison of direct and indirect methods. Clin Genet. Jan 1992;41(1):12-5. [Medline].

  3. Cohen MM Jr. Perspectives on craniosynostosis. Am J Med Genet. 2005;136:313-326.

  4. Anderson PJ, Hall C, Evans RD. The cervical spine in Crouzon syndrome. Spine. Feb 15 1997;22(4):402-5. [Medline].

  5. Hoefkens MF, Vermeij-Keers C, Vaandrager M. Crouzon syndrome: phenotypic signs and symptoms of the postnatallyexpressed subtype. J Craniofac Surg. 15;2004:233-240.

  6. Reardon W, Winter RM, Rutland P. Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet. Sep 1994;8(1):98-103. [Medline].

  7. Rutland P, Pulleyn LJ, Reardon W. Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes. Nat Genet. Feb 1995;9(2):173-6. [Medline].

  8. Wilkie AO, Slaney SF, Oldridge M. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet. Feb 1995;9(2):165-72. [Medline].

  9. Muenke M, Gripp KW, McDonald-McGinn DM, et al. A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. Am J Hum Genet. Mar 1997;60(3):555-64. [Medline].

  10. Arnaud-Lopez L, Fragoso R, Mantilla-Capacho J, Barros-Nunez P. Crouzon with acanthosis nigricans. Further delineation of the syndrome. Clin Genet. 2007;72:405–410.

  11. Tay T, Martin F, Rowe N, Johnson K, Poole M, Tan K, et al. Prevalence and causes of visual impairment in craniosynostotic syndromes. Clin Experiment Ophthalmol. 2006;34:434-440.

  12. Gray TL, Casey T, Selva D, Anderson PJ, David DJ. Ophthalmic sequelae of Crouzon syndrome. Ophthalmology. Jun 2005;112(6):1129-34. [Medline].

  13. Scafati CT, Aliberti F, Scarfati ST, Mangone GM, Scafati MT. The Value of the maxillo-malar osteotomy in the treatment of Crouzon syndrome with exorbitism. Ann Plast Surg. 2008;61:285–289.

  14. Chen H. Crouzon syndrome. In: Atlas of Genetic Diagnosis and Counseling. Totowa, New Jersey: Humana Press; 2006:261-264.

  15. Robin NH, Falk MJ, Haldemen-Englert CR. FGFR-related craniosynostosis syndrome. GeneReviews. September, 2007;[Full Text].

  16. [Guideline] Cunniff C. Prenatal screening and diagnosis for pediatricians. Pediatrics. Sep 2004;114(3):889-94. [Medline][Full Text].

  17. Schwartz M, Kreiborg S, Skovby F. First-trimester prenatal diagnosis of Crouzon syndrome. Prenat Diagn. Feb 1996;16(2):155-8. [Medline].

  18. Abou-Sleiman PM, Apessos A, Harper JC, et al. Pregnancy following preimplantation genetic diagnosis for Crouzon syndrome. Mol Hum Reprod. Mar 2002;8(3):304-9. [Medline].

  19. Anderson PJ, Hall C, Evans RD, Harkness WJ, hayward RD, Jones BM. The cervical spine in Crouzon syndrome. Spine. 1997;22:402-405.

  20. Bresnick S, Schendel S. Crouzon's disease correlates with low fibroblastic growth factor receptor activity in stenosed cranial sutures. J Craniofac Surg. May 1995;6(3):245-8. [Medline].

  21. Chen CP, Lin SP, Su YN, Huang JK, Wang W. A cloverleaf skull associated with Crouzon syndrome. Arch Dis Child Fetal Neonatal Ed. Mar 2006;91(2):F98. [Medline].

  22. Cinalli G, Renier D, Sebag G, et al. Chronic tonsillar herniation in Crouzon's and Apert's syndromes: the role of premature synostosis of the lambdoid suture. J Neurosurg. Oct 1995;83(4):575-82. [Medline].

  23. Cohen MM. An etiologic and nosologic overview of craniosynostosis syndromes. Birth Defects Orig Artic Ser. 1975;11(2):137-89. [Medline].

  24. Cohen MM Jr. Craniosynostosis update 1987. Am J Med Genet Suppl. 1988;4:99-148. [Medline].

  25. David DJ, Sheen R. Surgical correction of Crouzon syndrome. Plast Reconstr Surg. Mar 1990;85(3):344-54. [Medline].

  26. de Ravel TJ, Taylor IB, Van Oostveldt AJ, et al. A further mutation of the FGFR2 tyrosine kinase domain in mild Crouzon syndrome. Eur J Hum Genet. Apr 2005;13(4):503-5. [Medline].

  27. Do Amaral CMR, Di Domizio G, Buzzo CL. Surgical treatment of Apert syndrome and Crouzon anomaly by gradual bone distraction. Online J Plast Reconstr Surg. 1998;1 July.

  28. Fjortoft MI, Sevely A, Boetto S, et al. Prenatal diagnosis of craniosynostosis: value of MR imaging. Neuroradiology. Jun 2007;49(6):515-21. [Medline].

  29. Gorry MC, Preston RA, White GJ. Crouzon syndrome: mutations in two spliceoforms of FGFR2 and a common point mutation shared with Jackson-Weiss syndrome. Hum Mol Genet. Aug 1995;4(8):1387-90. [Medline].

  30. Hollway GE, Suthers GK, Haan EA. Mutation detection in FGFR2 craniosynostosis syndromes. Hum Genet. Feb 1997;99(2):251-5. [Medline].

  31. Jabs EW, Li X, Scott AF, et al. Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. Nat Genet. Nov 1994;8(3):275-9. [Medline].

  32. Jarund M, Lauritzen C. Craniofacial dysostosis: airway obstruction and craniofacial surgery. Scand J Plast Reconstr Surg Hand Surg. Dec 1996;30(4):275-9. [Medline].

  33. Liptak GS, Serletti JM. Pediatric approach to craniosynostosis [published erratum appears in Pediatr Rev 1999 Jan;20(1):20]. Pediatr Rev. Oct 1998;19(10):352; quiz 359. [Medline].

  34. Meyers GA, Day D, Goldberg R. FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: evidence for missense changes, insertions, and a deletion due to alternative RNA splicing. Am J Hum Genet. Mar 1996;58(3):491-8. [Medline].

  35. Meyers GA, Orlow SJ, Munro IR. Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet. Dec 1995;11(4):462-4. [Medline].

  36. Nagase T, Nagase M, Hirose S, Ohmori K. Crouzon syndrome with acanthosis nigricans: case report and mutational analysis. Cleft Palate Craniofac J. Jan 2000;37(1):78-82. [Medline].

  37. Park WJ, Meyers GA, Li X. Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variability. Hum Mol Genet. Jul 1995;4(7):1229-33. [Medline].

  38. Prevel CD, Eppley BL, McCarty M. Acrocephalosyndactyly syndromes: a review. J Craniofac Surg. Jul 1997;8(4):279-85. [Medline].

  39. Wilkes D, Rutland P, Pulleyn LJ. A recurrent mutation, ala391glu, in the transmembrane region of FGFR3 causes Crouzon syndrome and acanthosis nigricans. J Med Genet. Sep 1996;33(9):744-8. [Medline].

Further Reading

Keywords

acrocephalosyndactyly type II, craniofacial dysostosis, craniostenosis Crouzon type, Crouzon craniofacial dysostosis, calvarial deformities, facial anomalies, exophthalmos, craniosynostosis, Crouzon syndrome, Crouzon's syndrome, hypertelorism, exophthalmos, strabismus, beaked nose, short upper lip, hypoplastic maxilla, mandibular prognathism, fibroblast growth factor receptor-2, FGFR2 gene, FGFR3 gene, FGFR1 gene, upper airway obstruction, respiratory distress, septal deviation, conductive deafness, Ménière disease

Contributor Information and Disclosures

Author

Harold Chen, MD, MS, FAAP, FACMG, Professor, Departments of Pediatrics, Obstetrics and Gynecology, and Pathology, Director of Genetic Laboratory Services, Louisiana State University Medical Center
Harold Chen, MD, MS, FAAP, FACMG is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society of Human Genetics, and Teratology Society
Disclosure: Nothing to disclose.

Medical Editor

Michael Fasullo, PhD, Senior Scientist, Ordway Research Institute; Associate Professor, State University of New York at Albany; Adjunct Associate Professor, Center for Immunology and Microbial Disease, Albany Medical College
Michael Fasullo, PhD is a member of the following medical societies: Radiation Research Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

David Flannery, MD, FAAP, FACMG, Vice Chair of Education, Chief, Section of Medical Genetics, Professor, Department of Pediatrics, Medical College of Georgia
David Flannery, MD, FAAP, FACMG is a member of the following medical societies: American Academy of Pediatrics and American College of Medical Genetics
Disclosure: Nothing to disclose.

CME Editor

Paul D Petry, DO, FACOP, FAAP, Consulting Staff, Freeman Pediatric Care, Freeman Health System
Paul D Petry, DO, FACOP, FAAP is a member of the following medical societies: American Academy of Osteopathy, American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association
Disclosure: Nothing to disclose.

Chief Editor

Bruce Buehler, MD, Professor of Genetics, Munroe Meyer Institute, Professor, Department of Pediatrics, Pathology and Microbiology, University of Nebraska Medical Center
Bruce Buehler, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Pediatrics, American Association on Mental Retardation, American College of Medical Genetics, American College of Physician Executives, American Medical Association, and Nebraska Medical Association
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.